Literature DB >> 20705881

Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence.

Adrienne Einarson.   

Abstract

QUESTION: I have a patient who has just found out she is pregnant, and she is currently taking paroxetine for severe anxiety and depression. Owing to conflicting results from different studies, as well as my patient hearing about the lawsuit against GlaxoSmithKline, I did try her on other antidepressants; however, only paroxetine was effective, so she restarted it. Now she is pregnant and euthymic, but she is extremely worried about taking the drug. How do I explain the confusing information to her? ANSWER: There has recently been an increase in the publication of studies reporting pregnancy outcomes associated with use of antidepressants; many focus on paroxetine, often with conflicting results. However, despite these studies and the precedent-setting lawsuit in which GlaxoSmithKline was ordered to pay $2.5 million to the family of a child with a heart defect whose mother took paroxetine in the first trimester of pregnancy, the evidence that paroxetine increases the rate of cardiac malformations above the population baseline risk of 1 out of 100 pregnancies just does not exist.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705881      PMCID: PMC2920776     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  13 in total

1.  Paroxetine exposure during pregnancy and the risk of cardiac malformations: what is the evidence?

Authors:  Anick Bérard
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-03

2.  Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations.

Authors:  Bengt A J Källén; Petra Otterblad Olausson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2007-04

3.  Risks associated with selective serotonin reuptake inhibitors in pregnancy.

Authors:  Heli Malm; Timo Klaukka; Pertti J Neuvonen
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

4.  Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies.

Authors:  Thomas R Einarson; Adrienne Einarson
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-12       Impact factor: 2.890

5.  Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy.

Authors:  Adrienne Einarson; Alessandra Pistelli; Marco DeSantis; Heli Malm; Wolfgang D Paulus; Alice Panchaud; Debra Kennedy; Thomas R Einarson; Gideon Koren
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

6.  First-trimester use of paroxetine and congenital heart defects: a population-based case-control study.

Authors:  Marian K Bakker; Wilhelmina S Kerstjens-Frederikse; Charles H C M Buys; Hermien E K de Walle; Lolkje T W de Jong-van den Berg
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-02

7.  Paroxetine in the first trimester and the prevalence of congenital malformations.

Authors:  J Alexander Cole; Sara A Ephross; Irene S Cosmatos; Alexander M Walker
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-10       Impact factor: 2.890

8.  First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies.

Authors:  Keele E Wurst; Charles Poole; Sara A Ephross; Andrew F Olshan
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-03

Review 9.  The incidence of congenital heart disease.

Authors:  Julien I E Hoffman; Samuel Kaplan
Journal:  J Am Coll Cardiol       Date:  2002-06-19       Impact factor: 24.094

10.  Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study.

Authors:  Lars Henning Pedersen; Tine Brink Henriksen; Mogens Vestergaard; Jørn Olsen; Bodil Hammer Bech
Journal:  BMJ       Date:  2009-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.